MindWalk Holdings Business Summary

MindWalk Holdings Corp. (HYFT), formerly ImmunoPrecise Antibodies Ltd., operates as a "Bio-Native AI" biotherapeutic research and technology company. The company generates revenue through a dual-stream model: project-based fees from its comprehensive Contract Research Organization (CRO) services—including B cell Select, Phage Display, and protein manufacturing—and platform-related revenue derived from its proprietary HYFT® technology and LensAI™ software. By integrating in silico computational modeling with a full-stack wet lab, MindWalk unifies biological sequence, structure, and function into a single language to accelerate drug discovery. Its primary business segments are divided between high-margin AI-driven asset discovery and traditional laboratory services, positioning the company as a specialized player in the life sciences data analytics market. Direct competitors include Abcellera Biologics, Ginkgo Bioworks, and MaxCyte; MindWalk distinguishes itself by leveraging its patented HYFT patterns to provide deep-data insights that bridge the gap between computational discovery and clinical validation. The leadership team is led by President and CEO Dr. Jennifer Bath, a Ph.D. in Cellular and Molecular Biology with a pedigree that includes executive roles at Aldevron and a tenured professorship. She is supported by CFO R. Scott Areglado, who joined in October 2025 with over 25 years of financial leadership at BrainsWay and iCAD, and Chief Business Officer Dr. Thomas W. Lynch, an industry veteran from Aldevron and DNASTAR. The company’s technological core is directed by CTO Dr. Dirk Van Hyfte, a serial entrepreneur and MD/Ph.D. who founded BioStrand BV. MindWalk’s board of directors includes notable industry figures such as Jon Lieber, current CFO of Rallybio, and Dirk Witters, a former executive at KBC Group. Institutional backing is provided by firms such as BMO Asset Management Corp., reflecting a strategic focus on scaling the company's AI-native intelligence platform globally.